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OBJECTIVE: Thymosin beta 4 (Tb4) is a ubiquitous peptide that plays pivotal roles in the cytoskeletal system and
in cell differentiation. Recently, a role for Tb4 has been proposed in experimental and human carcinogenesis,
including gastrointestinal cancer. This study was aimed at evaluating the relationship between Tb4
immunoreactivity and the initial steps of carcinogenesis.
METHODS: In total, 60 intestinal biopsies, including 10 hyperplastic polyps, 10 sessile serrated adenomas/polyps,
15 colorectal adenomas with low-grade dysplasia, 15 adenomas with high-grade dysplasia, 15 adenocarcinomas
and 10 samples of normal colon mucosa, were analyzed for Tb4 expression by immunohistochemistry.
RESULTS: Weak cytoplasmic reactivity for Tb4 was detected in the normal colon mucosa. No reactivity for Tb4
was found in hyperplastic and sessile serrated polyps/adenomas. Tb4 expression was observed in 10/15
colorectal adenocarcinomas. In adenomas with low-grade dysplasia, Tb4 immunoreactivity was mainly detected
in dysplastic glands but was absent in hyperplastic glands. Tb4 immunoreactivity was characterized by spot-like
perinuclear staining. In high-grade dysplastic polyps, immunostaining for Tb4 appeared diffuse throughout the
entire cytoplasm of dysplastic cells. Spot-like perinuclear reactivity was detected in adenocarcinoma tumor cells.
CONCLUSIONS: Our study shows for the first time that Tb4 is expressed during different steps of colon
carcinogenesis. The shift of Tb4 immunolocalization from low-grade to high-grade dysplastic glands suggests a
role for Tb4 in colorectal carcinogenesis. However, the real meaning of Tb4 reactivity in dysplastic intestinal
epithelium remains unknown.
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Thymosin beta 4 (Tb4), a peptide named after its first
detection in the calf thymus (1), is a member of the b-
thymosins, a versatile actin-binding protein family (2). Tb4
has traditionally been associated with a role as a regulator of
actin polymerization in living cells (3). Tb4 is thought to be
involved in many critical biological processes, including
angiogenesis (4), wound healing (5), the inflammatory
response (6) and cell migration (7). Tb4 may also stimulate
the AKT pathway, resulting in a strong anti-apoptotic effect
on human cells (7), and it has recently been documented to
play an essential role in cardioprotection after myocardial
infarction (8) and in the protection of gingival fibroblasts
from apoptosis induced by TNF-a (9). Recently, Tb4 activity
was implicated in experimental and human carcinogenesis.
This concept is mainly based on the observation that Tb4
may facilitate tumor cell motility and induce intra- and
peritumoral angiogenesis (10). Tb4 has been recently
documented in breast cancer and in a few cases of colorectal
cancer (11). Possible pro-metastatic (12) and pro-angiogenic
activity has been hypothesized for Tb4 (13), which has
encouraged the development of Tb4 inhibitors as anti-
cancer drugs (14). Recently, Tb4 immunoreactivity was
detected by our group in the vast majority of colon
carcinomas, where it showed a patchy distribution and
well-differentiated areas that were significantly more
reactive than less-differentiated tumor zones. Moreover,
the localization of Tb4 changed during cancer progression,
moving from the cell membrane to the Golgi apparatus (15).
On the basis of these data, this study was aimed at
analyzing the expression of Tb4 in the initial steps of
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colorectal carcinogenesis. We analyzed Tb4 expression by
immunohistochemistry in hyperplastic polyps and color-
ectal adenomas with different degrees of dysplasia to shed
light on the relationship between Tb4 expression and colon
cancer insurgence and progression.
& MATERIALS AND METHODS
The study included archival paraffin-embedded color-
ectal biopsies obtained from 75 patients who underwent
colonoscopy and biopsy. The cohort included six groups:
normal colon mucosa (10 samples), hyperplastic polyps (10
samples), sessile serrated adenomas/polyps (10 samples),
adenomas with low-grade dysplasia (15 samples), adeno-
mas with high-grade dysplasia (15 samples) and adenocar-
cinomas (15 samples). Dysplasia was graded according to
the degree of nuclear atypia and glandular architectural
changes (16).
Paraffin sections were immunostained with anti-Tb4
antibodies using the labeled streptavidin-biotin complex
system (LSAB2, Dako) in a Dako Autostainer (Dako-
Cytomation, Carpinteria, CA, USA). Briefly, slides were
deparaffinized and rehydrated, and endogenous peroxidase
activity was quenched (30 min) by 0.3% hydrogen peroxide
in methanol. The slides were then subjected to heat-induced
antigen retrieval by steaming unstained sections in Target
Retrieval Solution (Dako TRS pH 6.1) for 30 min. Next, the
slides were incubated with 10% normal goat serum in
phosphate-buffered saline (PBS) for 60 min to block non-
specific binding, followed by incubation (60 min at room
temperature) with a monoclonal anti-Thymosin Beta 4
antibody (Bachem-Peninsula Lab, San Carlos, CA, USA),
diluted 1:100 in the blocking solution. Slides were exten-
sively washed with PBS containing 0.01% Triton X-100 and
incubated with a secondary reagent (En Vision kit) accord-
ing to the manufacturer’s (Dako, Glostrup, Denmark)
instructions. Diaminobenzidine (DAB) was used as a
chromogen. After additional washes, the color was devel-
oped using AEC reagent (Dako), and the sections were
counterstained with Mayer’s hematoxylin and mounted.
Sections of reactive lymph nodes with Tb4-immunoreactive
histiocytes were utilized as positive controls. For negative
controls, the same procedure was applied, omitting the
primary antibody. All cases were independently analyzed
by two pathologists specialized in gastrointestinal pathol-
ogy (SN, GF).
& RESULTS
In this study, Tb4 expression was always restricted to the
cytoplasm of normal and dysplastic cells. No nuclear
reactivity was detected in intestinal cells. Four main
patterns of immunostaining for Tb4 were observed, as
follows: a) granular cytoplasmic staining, localized to the
entire cytoplasm or to the apical regions of the enterocytes
and possibly representative of the localization of the peptide
in vesicles; b) spot-like perinuclear immunostaining, possi-
bly representative of Tb4 localization in the trans-Golgi
network, c) homogeneous cytoplasmic staining, probably
marking the actin-binding activity of the peptide, and d)
intraluminal granular reactivity. No significant differences
regarding Tb4 immunoreactivity were detected within the
first five groups, whereas inter-individual differences were
only found for the intensity of immunostaining. Marked
individual differences were observed in cases of colon
cancer, in which Tb4 was expressed in 10 of 15 cases.
Normal colon mucosa
All specimens of human colonic mucosa showed cyto-
plasmic expression of Tb4. Immunoreactivity for Tb4 was
detected in the superficial enterocytes and in crypt cells.
Immunoreactivity was consistently restricted to the cyto-
plasm and appeared as homogeneous staining. Tb4 was also
found in granular deposits in the intestinal lumen that were
dispersed in the mucous secretions.
Hyperplastic polyps and sessile serrated polyps/
adenomas
Hyperplastic glands and sessile serrated polyps/adeno-
mas did not show any significant reactivity for Tb4. Intense
and granular cytoplasmic positivity was occasionally
detected in scattered stromal mast cells (Figures 1A and 1B).
Adenomas with low-grade dysplasia
In adenomas with low-grade dysplasia, Tb4 reactivity
observed at low magnification appeared to be homoge-
neously present in all of the observed dysplastic glands
(Figure 1C). No notable staining for Tb4 was detected in
hyperplastic gland cells. At higher magnification, three
main patterns of reactivity were observed in dysplastic
glands: i) a punctate granular pattern observed in the entire
cytoplasm; ii) a band-like pattern occupying the apical zone
of the proliferating enterocytes; and iii) spot-like perinuclear
reactivity (Figure 1D).
Adenomas with high-grade dysplasia
When we studied Tb4 expression in colon adenomas with
high-grade dysplasia, we found significant differences from
low-grade dysplastic adenomas. Immunoreactivity for Tb4
appeared to be more diffuse throughout the cytoplasm of
dysplastic cells (Figure 1E). In tubulo-villous adenomas, Tb4
was mainly expressed in the cytoplasm of superficial
dysplastic epithelial cells (Figure 1F).
Adenocarcinoma
Immunoreactivity for Tb4 was detected in 10 out of 15
adenocarcinomas immunostained for the peptide. The most
frequent immunohistochemical pattern was characterized
by the accumulation of Tb4 in the perinuclear area, giving
rise to spot-like reactivity highly suggestive of localization
to the trans-Golgi Network (Figure 1G). Granular discrete
reactivity for Tb4 was also detected in the stroma in close
proximity to the glands with infiltrating tumors (Figure 1H).
& DISCUSSION
This study comprehensively investigated the Tb4 protein
expression pattern in human colorectal polyps and adeno-
mas, showing relevant changes in Tb4 localization in
enterocytes during different steps of colon carcinogenesis.
In previous studies, Tb4 was found to be expressed in
cultured colon carcinoma cells (17). Subsequent data
showed that Tb4 overexpression was associated with a
more malignant phenotype and with enhanced tumor cell
invasion, which suggests that Tb4 expression is associated
with tumor aggressiveness and poor survival (18). A study
investigating Tb4 expression in a limited number of human
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Figure 1 - Hyperplastic and serrated hyperplastic polyps: A), B) No immunoreactivity for Tb4 was observed in hyperplastic and serrated
hyperplastic glands of the polyps analyzed. Scattered mast cells showed an intense and granular positivity for Tb4 (OM X250 and X 100).
Adenoma with low-grade dysplasia: C) at low magnification, the diffuse cytoplasmic immunoreactivity for Tb4 was restricted to the
dysplastic crypt epithelium (OM x100); D) at higher magnification, three main patterns of reactivity for Tb4 were observed in the
dysplastic glands: perinuclear spots, cytoplasmic granules and homogeneous cytoplasmic immunostaining (OM x400); adenoma with
high-grade dysplasia: E) at low magnification, intense cytoplasmic immunoreactivity for Tb4 was observed in the cytoplasm of dysplastic
cells (OMX100); F) at higher magnification, diffuse and homogeneous Tb4 immunoreactivity was observed in the cytoplasm of
dysplastic glands (OMx400); adenocarcinoma: G) at higher magnification, peri-nuclear spot-like reactivity for Tb4 was observed in the
cytoplasm of the neoplastic nest (OMx400); H) perinuclear spot-like reactivity for Tb4 was observed in the cytoplasm of the infiltrating
tumor glands. Fine granular immunoreactivity was detected in the stroma surrounding the infiltrating tumor glands (OMx250).
Tß4 in colon adenomas
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colon cancers reported highly variable immunostaining for
Tb4 in tumor cells and in endothelial and stromal cells (10).
A recent study from our group showed strong Tb4
cytoplasmic immunostaining in the tumor cells of the vast
majority of colorectal adenocarcinomas (15). In this study,
Tb4 expression was found even in adenomas with low-
grade dysplasia, representing the earliest stage of colorectal
tumorigenesis. Further increases in Tb4 expression paral-
leled the progression through distinct pathological stages,
namely low-grade dysplasia and high-grade dysplasia.
These findings clearly indicate that Tb4 plays a role in
colorectal carcinogenesis, starting from the early stages of
adenomatous polyps and continuing through the progres-
sion towards colorectal cancer. It remains unclear whether
Tb4 staining could serve as a biomarker to distinguish
colorectal adenomas that are more likely to progress to
adenocarcinoma from Tb4-negative polyps with no ten-
dency toward cancer progression; long-term follow up and
a large cohort of patients are required.
The absence of immunoreactivity for Tb4 in sessile
serrated polyps/adenomas is an interesting finding of our
study. This finding suggests that Tb4 could play a different
role in the ‘‘serrated’’ pathway of colorectal neoplasia. From
a practical point of view, the absence of immunoreactivity
for Tb4 in serrated polyps/adenomas might suggest the use
of anti-Tb4 antibodies in complex cases in which the
differential diagnosis between low-grade adenoma and
serrated polyp/adenoma is uncertain, based exclusively
upon morphological criteria.
Colon cancer progression has also been associated with
modifications in Tb4 subcellular localization. In normal
human colon mucosa, Tb4 has a homogeneously diffuse
staining pattern in the cytoplasm of superficial enterocytes
and in the crypt epithelium. In hyperplastic polyps, we
observed a complete disappearance of immunoreactivity for
Tb4. Interestingly, in low-grade dysplastic glands, we
observed a preferential localization of Tb4 to the trans-
Golgi network, evidenced by perinuclear spot reactivity.
The same immunostaining pattern for Tb4 was previously
reported in well-differentiated adenocarcinomas (15). In
contrast, in high-grade adenomas, the pattern of Tb4
immunolocalization changed to a cytoplasmic diffuse
pattern. Although we were unable to attribute a certain
function to Tb4, particularly to its translocation to the Golgi
apparatus and then back to the cytoplasm during colon
carcinogenesis, we speculate that the diffuse cytoplasmic
reactivity observed in normal mucosa could reflect the
primary physiological role of Tb4, i.e., the maintenance of
actin cytoskeleton integrity, on which cell morphogenesis
and motility depend (19). The translocation of Tb4 from
cytoplasmic vesicles to the trans-Golgi network may suggest
a new function for this peptide in low-grade dysplastic cells;
however, to the best of our knowledge, this function
remains unclear. Translocation from the cell membrane to
the trans-Golgi network has previously been reported in
liver cells for ATP7B, a copper-transporting P-type ATPase.
The localization of ATP7B in the Golgi apparatus reflects a
synthetic role in the incorporation of copper atoms in
cuproenzymes; under copper stress, ATP7B is relocated to
the cell membrane and utilized in the excretion of excess
copper (20). On the basis of these data, Tb4 may play diverse
roles in normal, dysplastic and tumor cells. Herein, we
reported the preferential localization of Tb4 in the Golgi
apparatus in dysplastic and neoplastic cells, which may
suggest a role for Tb4 in the secretory pathways of
dysplastic enterocytes and in colon cancer cells. The absence
of significant differences at the mRNA level between the
normal colon mucosa and tumor tissues was previously
reported by our group (15) and may suggest a deregulation
of Tb4 expression at the post-transcriptional level.
Recently, Tb4 has been shown to be widely expressed in
the gastrointestinal tract (21) and in the salivary glands (22)
during human embryogenesis, whereas its expression is low
or absent in many normal adult tissues. On the basis of the
present data, Tb4 could be added to the list of proteins
involved in both the embryogenesis and carcinogenesis of
the oral-gastrointestinal tract (23).
In summary, the present study demonstrated that Tb4 is
frequently expressed and usually deregulated in human
colon adenomas and is preferentially localized in the trans-
Golgi network in low-grade dysplasia, in the whole
cytoplasm in high-grade dysplasia, and back to the Golgi
apparatus in colon cancer. These findings suggest that Tb4
translocation occurs during both the initial and the
advanced stages of tumor progression in colorectal cancer.
Identifying the molecular mechanism underlying this
process is a major challenge for future research focusing
on Tb4 in human colon carcinogenesis. The well-known role
of Tb4 in the recruitment and stimulation of adult and
progenitor cells to restore their embryonic pluripotency (19),
together with its strong expression in all stages of colorectal
carcinogenesis, leads us to hypothesize that Tb4 may drive
the development of colorectal adenocarcinoma during
multistage carcinogenesis. Further studies at the molecular
level are needed to validate these immunohistochemical
results with other analytical methods.
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